Cholesterol-lowering activity of naringenin via inhibition of 8-hydroxy-3-methylglutaryl coenzyme a reductase and acyl coenzyme A:cholesterol acyltransferase in rats

Annals of Nutrition and Metabolism

Volumn 43, Issue 3, 1999, Pages 173-180

  Lee, S H ^a   Park, Y B ^b   Bae, K H ^c   Bok, S H ^d   Kwon, Y K ^d   Lee, E S ^d   Choi, M S ^a,b  

^a Dept of Nutr and Food Science ^*  (South Korea)

^b Kyungpook National University   (South Korea)

^c Chungnam National University   (South Korea)

^d Korea Institute of Science and Technology   (South Korea)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase; Acyl coenzyme A:cholesterol O acyltransferase; High cholesterol diet; Liver cholesterol; Naringenin; Plasma cholesterol

Indexed keywords

ACYL COENZYME A; BIOFLAVONOID; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER ENZYME; NARINGENIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; LIPID BLOOD LEVEL; LIPID LIVER LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STEROL EXCRETION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CHOLESTEROL; CHOLESTEROL, DIETARY; ENZYME INHIBITORS; FECES; FLAVANONES; FLAVONOIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; STEROL O-ACYLTRANSFERASE; STEROLS;

ANIMALIA; CITRUS;

EID: 0032725927     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012783     Document Type: Article

References (47)

1. Wald NJ, Law MR: Serum cholesterol and ischaemic heart disease. Atherosclerosis 1995;118(suppl):1-5.
2. Alberts AW, Chen J, Kuron G, et al: Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77:3957-3961.
3. Amin D, Gustafson SK, Weinacht JM, et al: RG 12561 (Dalvastatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology 1993;46:13-22.
4. Alberts W: Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988;62:10J-15J.
5. Fujioka T, Nara F, Tsujita Y, et al: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim Biophys Acta 1995; 1254:7-12.
6. Lovastatin Study Groups I through IV: Lovastatin 5-year safety and efficacy study. Arch Intern Med 1993; 153:1079-1087.
7. Brown MS, Ho YK, Goldstein JL: The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem 1980;255:9344-9352.
8. Kannel WB, Casteri WP, Gondon T, et al: Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971;74:1-12.
9. Frick MH, Elso O, Haapa K, et al: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
10. Helgerud P, Sarem K, Kare R: Norum. Acyl-CoA:cholesterol acyltransferase in human small intestine: Its activity and some properties of the enzyme reaction. J Lipid Res 1981;22:271-277.
11. Suckling KE, Stange EF: Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 1985;26:647-659.
12. Aboobaker VS, Balgi AD, Bhattacharya RK: In vivo effect of dietary factors on the molecular action of aflatoxin B1: Role of non-nutrient phenolic compounds on the catalytic activity of liver fraction. In Vivo 1994;8:1095-1098.
13. Buening MK, Chang RL, Huang MT, et al: Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 1981;41:67-72.
14. Hardigree AA, Epler JL: Comparative mutagenesis of plant flavonoids in microbial systems. Mutay Res 1978;58:231-239.
15. Basarkar PW, Nath N: Cholesterol lowering action of vitamin P-like compounds in rats. Indian J Exp Biol 1981;19:787-789.
16. Rathi AB, Nath N, Chari SN: Activation of vitamin P like compounds on lysosomal fragility in hypercholesterolemia: Implication of ascorbic acid and its metabolites. Acta Vitaminol Enzymol 1984;6:97-102.
17. Monforte MT, Trovato A, Kirjavainen S, et al: Biological effects of hcsperidin, a Citrus flavonoid (note II): Hypolipidemic activity on experimental liypercholesterolemia in rat. Farmaco 1995;50:595-599.
18. American Institute of Nutrition: Report of the American Institute of Nutrition. Ad Hoc Committee of Standards for Nutritional Studies. J Nutr 1977;107:1340-1348.
19. American Institute of Nutrition: Report of Ad Hoc Committee on Standards for Nutritional Studies. J Nutr 1980;110:1726.
20. Allain CC, Poon LS, Chan CSG, et al: Enzymatic determination of total serum cholesterol. Clin Chem 1974; 20:470-475.
21. Warnick RG, Albers JJ: A comprehensive evaluation of the heparinmanganease precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19:65-76.
22. McGowan MW, Artiss JD, Strandbergh DR, et al: A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983;29:538-542.
23. Folch J, Lees M, Sloan-Stanley GH: A simple method for isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226: 497-509.
24. Omodeo Sale, Marchesini S, Fishman PH, et al: A sensitive enzymatic assay for determination of cholesterol in lipid extract. Anal Biochem 1984;142:347-350.
25. Czubayko F, Beumers B, Lammsfuss S, et al: A simplified micromethod for quantification of fecal excretion of neutral and acidic sterols for outpatient studies in humans. J Lipid Res 1991;32:1861-1867.
26. Hulcher FH, Oleson WH: Simplified spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl CoA reductase by measurement of coenzyme A. J Lipid Res 1973;14:625-631.
27. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248-254.
28. Shapiro DJ, Nordstrom JL, Mitschelen JJ, et al: Micro assay for 3-hydroxy-3-methylglutaryl-CoA reductase in rat liver and in L-cell fibroblasts. Biochim Biophys Acta 1974;370:369-377.
29. Erickson SK, Schrewsbery MA, Brooks C, et al: Rat liver acyl-coenzyme A: cholesterol acyltransferase: Its regulation in vivo and some of properties in vitro. J Lipid Res 1980;21:930-941.
30. Gillies PJ, Rathgeb KA, Robinson CS: Regulation of acyl-CoA:cholesterol acyltransferase activity in normal and atherosclerotic rabbit aortas: Role of a cholesterol substrate pool. Exp Mol Pathol 1986;44:320-339.
31. Endo A: The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-1582.
32. Fears R, Richards DH, Ferres H: The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 1980;35:439-449.
33. Endo A, Tsujita Y, Kuroda M, et al: Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals. Biochim Biophys Acta 1979;575:266-276.
34. Ma PTS, Gil G, Sudhog TC, et al: Mevinolin, and inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci USA 1986;83:8370-8374.
35. Krause BR, Anderson M, Bisgaier CL, et al: In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rat is due to inhibition of both intestinal and liver ACAT. J Lipid Res 1993;34: 279-294.
36. Salisbury BG, Davis HR, Burrier RE, et al: Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption. SCH 48461. Atherosclerosis 1995;115:45-63.
37. Van Heek M, France CF, Compton DS, et al: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and Rhesus monkey through the identification of the active metabolites of SCH48461. Pharmacol Exp Ther 1997;283:157-163.
38. Schnitzer-Polokoff R, Compton D, Boykow G, et al: Effects of acyl-CoA:cholesterol O-acyltransferase inhibition of cholesterol absorption and plasma lipoprotein composition in hamsters. Comp Biochem Physiol A 1991;99:665-670.
39. Largis EF, Wang CH, DeVries VG, et al: CL 277082: A novel inhibitor of ACAT-catalysed cholesterol esterification and cholesterol absorption. J Lipid Res 1989;30:681-690.
40. Williams RJ, McCarthy AD, Sutherland CD: Esterification and absorption of cholesterol: In vitro and in vivo observations in the rat. Biochim Biophys Acta 1989;1003:213-216.
41. Marezetta CA, Savoy YE, Freeman AM, et al: Pharmacological properties of a novel ACAT inhibitor (CP-113,818) in cholesterol-fed rats, hamsters, rabbits, and monkeys. J Lipid Res 1994;35:1829-1838.
42. Harris WS, Dujovne CA, von Bergmann K, et al: Effects of the ACAT inhibitor CL 277,082 on cholesterol metabolism in humans. Clin Pharmacol Ther 1990;48:189-194.
43. Bjorkhem I: Mechanism of bile acid biosynthesis in mammalian liver; in Danielson H. Sjovall J (eds): New Comprehensive Biochemistry. Amsterdam, Elsevier Scientific, 1985, pp 231-278.
44. Field FJ, Cooper AD, Erickson SK: Regulation of rabbit intestinal acyl coenzyme A:cholesterol acyltransferase in vivo and in vitro. Gastroenterology 1982;83:873-880.
45. Carr TP, Parks JS, Rudel LL: Hepatic ACAT activity in African green monkeys in highly correlated to plasma LDL cholesteryl enrichment and coronary artery atherosclerosis. Arterioscler Thromb 1992; 12:1274-1283.
46. Shand JH, West DW: The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. Lipids 1995;30:917-926.
47. Choi JS, Yokozawa T, Oura H: Antihyperlipidemic effect of flavonoids from Prunus davidiana. J Nat Prod 1991;54:218-224.